Related Experiment Videos
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia
1BMT/Leukemia Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Road L592, Portland 97239, USA. deininge@ohsu.edu
Abstract:
Imatinib (STI571), a 2-phenylaminopyrimidine, specifically inhibits the tyrosine kinase activity of Abl, Kit, and platelet-derived growth factor receptor. Clinical trials in chronic myelogenous leukemia (CML), characterized by the constitutively active Bcr-Abl tyrosine kinase, and gastrointestinal stromal tumors, characterized by activating mutations of Kit, have shown excellent results. This success is proof of principle for the concept of molecularly targeted therapy: rational treatment based on the recognition of the causal lesion responsible for malignant growth. In this manuscript, the preclinical and clinical development of imatinib for the treatment of CML will be reviewed. Room will be given to problems and challenges that may be typical of molecularly targeted therapy in general, such as the emergence of resistance as a result of point mutations. Last, the question will be addressed, why imatinib is so successful, and whether its success might be reproducible in other malignant conditions.
Insights
Imatinib is a targeted therapy drug that successfully treats chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors by inhibiting specific tyrosine kinases. Its success validates molecularly targeted therapy, though challenges like drug resistance exist.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Imatinib (STI571) is a 2-phenylaminopyrimidine derivative targeting Abl, Kit, and platelet-derived growth factor receptor tyrosine kinases.
- Chronic myelogenous leukemia (CML) is driven by the Bcr-Abl tyrosine kinase, while gastrointestinal stromal tumors often harbor activating Kit mutations.
- The efficacy of imatinib in these conditions demonstrates the potential of molecularly targeted therapy.
Purpose of the Study:
- To review the preclinical and clinical development of imatinib for CML treatment.
- To discuss challenges associated with molecularly targeted therapies, such as acquired resistance.
- To explore the reasons for imatinib's success and its potential applicability to other cancers.
Main Methods:
- Review of preclinical data on imatinib's mechanism of action and efficacy.
- Analysis of clinical trial results for imatinib in CML and gastrointestinal stromal tumors.
- Discussion of resistance mechanisms and future directions for targeted therapy.
Main Results:
- Imatinib demonstrated excellent clinical results in CML and gastrointestinal stromal tumors.
- The drug's targeted inhibition of specific kinases proved effective against cancers driven by these alterations.
- Challenges like the emergence of resistance mutations were identified as potential limitations.
Conclusions:
- Imatinib's success validates molecularly targeted therapy as a rational treatment approach.
- Understanding resistance mechanisms is crucial for the long-term efficacy of targeted therapies.
- The principles underlying imatinib's success may be applicable to other malignant conditions.